December 1, 2008Clinical Orthopaedics and Related ResearchOpen Access

Risk Assessment Based on FDG-PET Imaging in Patients with Synovial Sarcoma

View Full Paper

Ask AI

Bookmark

Why the study?

Does (18)F-FDG-PET-derived SUV(max) predict survival in patients with synovial sarcoma?

Population

44 patients with synovial sarcoma before therapy and resection

Design

Cohort

Authors

JLJennifer W. LisleUniversity of Vermont JEJanet F. EaryUniversity of Wyoming JOJanet OʼSullivanScience Foundation Ireland

Discussion

Member takes

Implication

SUV(max) >4.35 may aid risk stratification in synovial sarcoma; leaves open prospective validation before changing practice.

Structured PICO

Does (18)F-FDG-PET-derived SUV(max) predict survival in patients with synovial sarcoma?

Population

44 patients with synovial sarcoma before therapy and resection

Intervention

(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging

Outcome

Overall survival and progression-free survivalhard clinical

Pretherapy FDG-PET SUV(max) > 4.35 is a useful prognostic marker for predicting decreased disease-free survival and higher recurrence risk in synovial sarcoma.

Cite This Study

Lisle et al. (2008) studied this question.

synapsesocial.com/papers/6a919f8286feae8fbdfef6a1 https://doi.org/10.1007/s11999-008-0647-z

View Full Paper

Ask AI

Bookmark